ESMO: Will Adaptimmune's SPEAR-T results in a rare sarcoma appease investors?

Cancer in newspaper clipping
Adaptimmune is one of the biotech companies developing personalized cell therapies to treat solid tumors. (PDPics/Pixabay)

Adaptimmune’s shares have dropped 70% this year, as a few key executives have departed amid disappointing clinical results for the company’s SPEAR-T cells to treat solid tumors. Now, the company is rolling out phase 1 data for its lead product it hopes will accelerate its push toward commercialization.

The company presented data from an ongoing phase 1 trial of ADP-A2M4 at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona. The therapy, which is made from T cells taken from individual patients, is being tested in 12 patients with synovial sarcoma. The company said that seven of the patients had a partial response to the treatment and four had stable disease.

The announcement was an update to data reported in May from the same trial, at which point only 3 of 8 patients assessed had achieved partial responses.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Elliot Norry, Adaptimmune’s interim chief medical officer, said in a statement that the new data, plus the FDA’s recent decision to grant orphan drug designation to ADP-A2M4, are “important positive steps to expedite further development” of the product.

SPEAR-T cells are made by collecting blood from patients, isolating two types of immune cells—CD4 and CD8 T cells—and genetically modifying them to optimize their ability to bind to receptors in a way that allows them to recognize and clear cancer cells. ADP-A2M4 is directed at an antigen called MAGE, which is expressed in several solid tumors.

RELATED: Adaptimmune R&D chief leaves at dawn of critical trial

The first generation of cell therapies, chimeric antigen receptor T-cell treatments, have revolutionized the treatment of blood cancers but have been difficult to translate to solid tumors. Adaptimmune is betting on T-cell receptor (TCR) technology to fill that void. In addition to ADP-A2M4, the company is developing TCR treatments for lung cancer, liver cancer and several other tumor types.

The company has hit some bumps along the way, including a partial clinical hold on a GlaxoSmithKline-partnered therapy and, more recently, the retirement of its CEO and departure of its head of research and development. But Adaptimmune is still working toward a 2022 commercialization of ADP-A2M4, which is a wholly owned asset.

Adaptimmune is among several biotechs working on TCR products to address solid tumors. They include TScan Therapeutics, which launched in July with $48 million to commercialize a cell-therapy platform for treating solid tumors that was developed at Harvard University. Another player in the space, TMunity Therapeutics, recently partnered with the University of California, San Francisco to develop a TCR treatment for a rare type of brain tumor called diffuse intrinsic pontine glioma.

Adaptimmune has started a phase 2 trial of ADP-A2M4 in sarcoma. It also has a separate phase 1 trial of the cell therapy combined with radiation, and it has started evaluating a follow-up SPEAR-T cell treatment in sarcoma and other tumors.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.